GC
GBT

Grace Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Grace Capital’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$3.83M Buy
130,949
+2,300
+2% +$71.2K 2.28% 11
2021
Q3 		$3.97M Buy
128,649
+2,400
+2% +$70.5K 2.44% 8
2021
Q2 		$4.42M Sell
126,249
-3,900
-3% -$152K 2.96% 7
2021
Q1 		$5.3M Sell
130,149
-1,400
-1% -$64.3K 3.37% 4
2020
Q4 		$5.7M Buy
131,549
+6,800
+5% +$335K 3.6% 3
2020
Q3 		$6.88M Sell
124,749
-13,900
-10% -$883K 5.33% 2
2020
Q2 		$8.75M Sell
138,649
-7,780
-5% -$534K 7.52% 1
2020
Q1 		$7.48M Sell
146,429
-30,985
-17% -$2.08M 7.35% 1
2019
Q4 		$14.1M Sell
177,414
-64,600
-27% -$3.83M 11.5% 1
2019
Q3 		$11.7M Sell
242,014
-2,900
-1% -$151K 11.86% 1
2019
Q2 		$12.9M Sell
244,914
-19,100
-7% -$1.1M 6.14% 1
2019
Q1 		$14M Buy
264,014
+163,885
+164% +$8.05M 5.45% 1
2018
Q4 		$4.11M Sell
100,129
-212,385
-68% -$7.96M 1.91% 8
2018
Q3 		$11.9M Buy
312,514
+213,575
+216% +$9.46M 4.65% 1
2018
Q2 		$14M Buy
+98,939
New +$4.5M 5.34% 1

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Grace Capital's GBT Position: Q4 2021 in Review

Grace Capital increased its Global Blood Therapeutics, Inc. (GBT) stake by 1.8% in Q4 2021, buying an estimated $71.2K and bringing the position to 130,949 shares worth $3.83M. The position accounts for 2.28% of the portfolio, ranked #11.

Grace Capital first reported a position in GBT in Q2 2018 and has held it in 15 quarters since. The position peaked at $14.1M in Q4 2019. 206 funds tracked by Wall St. Rank hold GBT as of Q4 2021.

  • Grace Capital held 130,949 shares of Global Blood Therapeutics, Inc. worth $3.83M as of Q4 2021.
  • Grace Capital bought 2,300 Global Blood Therapeutics, Inc. shares in Q4 2021, an estimated $71.2K.
  • Global Blood Therapeutics, Inc. made up 2.28% of Grace Capital's portfolio in Q4 2021, its #11 holding.
  • Grace Capital first reported a position in Global Blood Therapeutics, Inc. in Q2 2018 and has held it in 15 quarters since.
  • Grace Capital's Global Blood Therapeutics, Inc. position peaked at $14.1M in Q4 2019.
  • 206 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2021.

Based on Grace Capital's 13F filing for Q4 2021, filed 2 Feb 2022.